Marketing Authorization. Seller authorizes Firm (Check ALL applicable sections): Signs. To place “For Sale,” “Under Contract,” “Sale Pending,” or other similar signs on the Property (where permitted by law and relevant covenants) and to remove other such signs. Open Houses. To conduct open houses of the Property at such times as Seller and Firm may subsequently agree.
Marketing Authorization. Seller acknowledges that Listing Broker has an obligation to release information to the multiple listing service (MLS) as to the final selling price, type of financing and number of days on market.
Marketing Authorization. Inform the SFDA of any adverse events that have occurred outside the KSA but have consequences for medical devices that have been authorized to be placed on the market of the KSA. The authorized representative shall explain the circumstances and provide information on the corrective action the manufacturer has taken or intends to take.
Marketing Authorization. MARKETING AUTHORIZATION applications shall be compiled by ORTHO based on information generated during the DEVELOPMENT program. Subject to Section 19.3.4, ORTHO shall own such MARKETING AUTHORIZATIONS. KOSAN shall prepare supporting documentation requested by ORTHO. At ORTHO's request and expense, KOSAN shall further assist ORTHO with the preparation of supporting data to apply for and pursue MARKETING AUTHORIZATIONS.
Marketing Authorization. Seller acknowledges that neither Listing Broker nor selling broker or any Multiple Listing Service is an insurer against the loss of the Seller’s personal property. Seller is advised to safeguard or remove valuables now located on said Property. Further, Seller acknowledges that Listing Broker may have an obligation to release information as to the amount of selling price, type of financing and number of days on market to any multiple listing service of which Listing Broker is a member.
Marketing Authorization. As between the Parties, Wyeth shall have the sole right and responsibility to take, and shall take, all actions with respect to the Product as would normally be taken in accordance with the accepted business practices and legal requirements in order to maintain the authorization to Market the Product as a pharmaceutical product in the Territory.
Marketing Authorization. The Company agrees that Aequitas may use the Company's name and logo, and general information concerning the Company's relationship with Aequitas, on the Aequitas website and in Aequitas firm brochures (typically in a form commonly known as "tombstones"), in press releases, advertisements, and in other related marketing materials. This authorization will extend to reissues of the advertisements and other marketing tools which Aequitas may utilize in its marketing activities. The Company may notify Aequitas in writing at any time to stop further use of references to Company in Aequitas marketing materials.
Marketing Authorization. 3.1.1 Subject to assignment thereof by Strakan to Aptalis, Aptalis will provide Strakan with a copy of the Product NDA or a suitable extract or summary of the relevant sections of the Product NDA, upon request, in order for Strakan to be able to discharge its responsibilities.
3.1.2 Aptalis will be responsible for informing the appropriate authorities of any future variation to the Product NDA and informing Strakan of the same.
Marketing Authorization. As between the PARTIES, XXXXXX shall be responsible for all development activities under the RESEARCH PLAN, all manufacturing activities associated with the manufacture of POTENTIAL PRODUCTS and COMMERCIAL PRODUCTS, all activities associated with the [***], and for the [***] for COMMERCIAL PRODUCTS. [***].
Marketing Authorization. In the event that Biomet elects not to obtain or maintain any regulatory license, approval, authorization or clearance necessary for the marketing and sale of the Product in the Field as an equipment platform in the Territory, BioCardia shall have the right to obtain the same. BioCardia shall have the exclusive right to generate preclinical data, conduct clinical trials and obtain Marketing Authorization for the use of mononuclear cells generated using the Product in the Field. For clarity, BioCardia shall have the exclusive right to seek, obtain and maintain Marketing Authorizations that are necessary or useful for the marketing and sale of the Product for specific therapeutic indications within the Field in the Territory. BioCardia will keep Biomet reasonably informed with respect to the status of the application, grant or maintenance of any such Marketing Authorization and Biomet agrees to reasonably cooperate with BioCardia with respect thereto, including by transferring Licensed Know-How necessary or useful for such purposes as requested by BioCardia pursuant to Section 4.2.
